|
Abstract To investigate the influence of preventive iron supplementation during pregnancy for treating pregnant women on their erythropoietin level and pregnancy outcomes. Methods: 100 pregnant women in the 11-12th gestational week were selected and were divided into study group and control group. The women in the study group were given preventive iron supplementation therapy from the 12th gestational week and the women in the control group were not given iron supplementation therapy. The clinical efficacy was compared between the two groups. Results: The incidences of iron deficiency (ID) and iron deficiency anemia (IDA) of women in the 28th and the 34th gestational week in the study group were 26.0%, 10.0%, 44.0%, and 16.0%, respectively, which were significant lower than those (60.0%, 36.0%, 90.0%, 44.0%, respectively) of women in the control group. Compared with those of women in the control group, the levels of erythropoietin, ferritin, hemoglobin, red blood cell volume, and related immune indexes of women in the study group had improved significantly. The rate of pregnancy complications and adverse pregnancy outcomes of women in the study group was 14.0%, which were significant lower than that (32.0%) of women in the control group (all P<0.05).Conclusion: The preventive iron supplementation therapy during pregnancy can prevent IDA of pregnant women effectively, and can significantly improve their immune function and decrease the incidences of pregnancy complications and adverse pregnancy outcomes.
|
|
|
|
|
|
